UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

THERAVANCE BIOPHARMA, INC.
(Name of Issuer)

Ordinary Shares
(Title of Class of Securities)

G8807B106
(CUSIP Number)
Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
England
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 4, 2016
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Cusip No. G8807B106	13 D/A1	Page 2 of 7	

1.	 	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

GlaxoSmithKline plc	 	 	
2.	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ☐
(b)    ☐	 	 	
3.	 	SEC USE ONLY
 	 	 	
4.	 	SOURCE OF FUNDS (see instructions)
 
WC	 	 	
5.	 	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐	 	 	
6.	 	CITIZENSHIP OR PLACE OF ORGANIZATION
 
England and Wales	 	 	

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	 	7.	 	SOLE VOTING POWER
 
9,644,807	 	
 	 	8.	 	SHARED VOTING POWER
 
-0-	 	 	
 	 	9.	 	SOLE DISPOSITIVE POWER
 
9,644,807	 	 	 	
 	 	10.	 	SHARED DISPOSITIVE POWER
 
-0-	 	 	 	

11.	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,644,807	 	 	
12.	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)    ☐	 	 	
13.	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

20.3%  (1)	 	 	
14.	 	TYPE OF REPORTING PERSON (see instructions)

CO	 	 	
Footnotes:	 	 	 	 	
 	
(1)           Based on 47,421,691 Ordinary Shares outstanding as of May 4, 2016.	

Cusip No. G8807B106	13 D/A1	Page 3 of 7	
Item 1.  Security and Issuer.
This Amendment No. 1 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on March 24, 2015, with respect to the Ordinary Shares, par value $0.00001 per share (the “Ordinary Shares”), of Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Issuer”). GlaxoSmithKline plc is filing this amendment to reflect its new percentage beneficial ownership in the Issuer, which has decreased as a result of an increase in the outstanding Ordinary Shares of the Issuer. The Issuer’s principal executive offices are located at PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.
Item 5.  Interest in Securities of the Issuer.
 	(a)	GlaxoSmithKline plc beneficially owns 9,644,807 Ordinary Shares, which represents 20.3% of 47,421,691 Ordinary Shares outstanding as of May 4, 2016.	

Cusip No. G8807B106	13 D/A1	Page 4 of 7	

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: May 13, 2016
GLAXOSMITHKLINE PLC
 
By: /s/ Victoria A. Whyte	
Victoria A. Whyte
Authorized Signatory

Cusip No. G8807B106	13 D/A1	Page 5 of 7	
SCHEDULE 1
Name	 	Business Address	 	Principal Occupation or Employment	 	Citizenship	
Board of Directors	 	 	 	 	 	 	
Sir Andrew Witty	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Executive Director and Chief Executive Officer	 	British	
Professor Sir Roy Anderson	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	British	
Manvinder Singh Banga	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	Indian	
Stacey Cartwright	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	British	
Simon Dingemans	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Executive Director and Chief Financial Officer	 	British	
Lynn Elsenhans	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	US	
Dr. Jesse Goodman	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	US	
Sir Philip Hampton	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Chairman and Company Director	 	British	
Judy Lewent	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	US	

Cusip No. G8807B106	13 D/A1	Page 6 of 7	
 
Urs Rohner	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Company Director	 	Swiss	
Dr. Moncef Slaoui	 	2301 Renaissance Boulevard,
King of Prussia
PA, 19406
 	 	Executive Director and
Chairman, Global Vaccines	 	Moroccan, Belgian & US	
 	 	 	 	 	 	 	
Corporate Executive Team
 	 	 	 	 	 	 	
Sir Andrew Witty	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Executive Director and Chief Executive Officer	 	British	
Roger Connor	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	President, Global Manufacturing & Supply	 	Irish	
Simon Dingemans	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Executive Director and Chief Financial Officer	 	British	
Nick Hirons	 	980 Great West Road
Brentford
Middlesex
TW8 9GS	 	Senior Vice President, Global Ethics and Compliance	 	British & US	
Abbas Hussain	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	President,Global Pharmaceuticals	 	British	
David Redfern	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Chief Strategy Officer	 	British	

Cusip No. G8807B106	13 D/A1	Page 7 of 7	
 
Dr. Moncef Slaoui	 	2301 Renaissance Boulevard,
King of Prussia
PA, 19406
 	 	Executive Director
Chairman, Global Vaccines	 	Moroccan, Belgian & US	
Claire Thomas	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Senior Vice President,
Human Resources	 	British	
Philip Thomson	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Senior Vice President,  Communications and Government Affairs	 	British	
Daniel Troy	 	The Navy Yard
5 Crescent Drive
Philadelphia, PA
19112	 	Senior Vice President & General Counsel	 	US	
Dr. Patrick Vallance	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	President, Pharmaceuticals R&D	 	British	
Emma Walmsley	 	980 Great West Road
Brentford
Middlesex, England
TW8 9GS	 	Chief Executive Officer, GSK Consumer Healthcare	 	British